Elite Pharmaceuticals Inc (ELTP)

[Couch]

Dr. Stuart Apfel, Elite's Chief Medical Officer, commented, "We are honored to have been selected to present our findings at this year’s AAPM. This study illustrates the fact that varying ratios of the opioid and naltrexone, in a combination formulation, may impact differently on a subject’s euphoria and related sensations. We are not aware of any previous published studies that demonstrate this observation. The study suggests that the ratio of agonist to antagonist is an important consideration in combination drugs designed to deter tampering or abuse of opioid analgesics.”

Lynn Webster, M.D., head of Lifetree Clinical Research in Salt Lake City, and the lead investigator for the abuse-deterrent study, said, "Prescription drug abuse is a national crisis. If we are going to use powerful pain killers like opioids we need them to be less attractive to abuse. Elite is advancing a formulation which may help deter abuse while providing a medication that will be effective in treating intractable pain."